Visão geral da empresa
A clinical-stage biotechnology entity, Rallybio Corporation focuses on the development and commercialization of transformative therapies designed for patients suffering from severe and rare diseases. The company operates within the healthcare sector, specifically the biotechnology industry, which is characterized by high research and development costs and a reliance on successful product approvals to generate future revenue streams. Rallybio currently holds a market capitalization of $44.59M, reports annual revenue of $858,000, and employs a workforce of 14 individuals. These financial and operational figures indicate that the company operates on a micro-cap scale, suggesting it is in an early stage of its commercial lifecycle where revenue generation is limited relative to the substantial cash reserves held.
Saúde financeira
The company reported revenue of $858,000 over the trailing twelve months, while net income stood at a loss of $-8,978,000 and EBITDA was -$31,272,000. The significant disparity between the modest revenue figure and the substantial negative net income reveals a cost structure dominated by high operating expenses, typical of clinical-stage entities investing heavily in research and development before achieving commercial profitability. Free cash flow is reported at -$20,342,500, which indicates that the company is burning cash to fund its operations and pipeline advancement rather than generating operational liquidity from its current business activities. The gross margin is 0.0%, the operating margin is -2888.3%, and the profit margin is 0.0%; these metrics collectively highlight that the company is currently unprofitable on both a gross and bottom-line basis, with the operating margin figure reflecting the intense burn rate relative to the small revenue base. The balance sheet shows a cash position of $54.74M against a debt level of only $176,000, resulting in a debt-to-equity ratio of 0.30. This stark contrast between liquid assets and liabilities suggests a highly conservative balance sheet with minimal leverage, providing a substantial financial runway to support its clinical programs. The current ratio is 14.51, a figure that indicates exceptional short-term liquidity, meaning the company possesses more than fourteen times the current assets required to cover its current liabilities without immediate distress. Return on equity is -15.0% and return on assets is -30.1%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, a status expected for pre-revenue biotechnology firms focused on long-term product development.
Avaliação de valorização
The trailing twelve-month P/E ratio is N/A due to the lack of earnings, while the forward P/E is -1.56; this negative forward multiple implies that analysts or market models project continued negative earnings in the near term rather than an immediate return to profitability. The price-to-book ratio is 0.77, which indicates that the market is valuing the company at a discount to its book value, suggesting that the market price does not currently reflect a premium over the net asset value of the firm. Valuation is also assessed using the price-to-sales ratio of 51.97 and an EV/EBITDA of 0.32; these alternative metrics suggest that the market is pricing the company primarily on its pipeline potential and asset base rather than current profitability, given the extreme multiple relative to sales. The stock's 52-week trading range spans from a low of $1.76 to a high of $11.49, placing the current valuation context within a wide band of historical volatility. With a beta of -1.20, the stock exhibits negative correlation to the broader market, meaning its price tends to move inversely to the market index, resulting in price volatility that differs significantly from the standard risk profile of most large-cap equities.
Growth & Income
Revenue growth year-over-year is recorded at 484.2%, while earnings growth is N/A because the company has not yet achieved positive net income to measure growth against. Since earnings growth cannot be calculated due to negative earnings, the revenue expansion stands as the primary indicator of top-line progress, though the absolute revenue remains small relative to the significant operating expenses. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders but instead retains all available capital. This reinvestment strategy is consistent with biotechnology firms that prioritize funding clinical trials and research over providing income to investors. The overall growth and income profile reflects a high-risk, high-reward dynamic where significant revenue expansion is occurring without corresponding profitability, and income generation is entirely absent as the firm focuses on future therapeutic commercialization.